• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    CRO Market Insights

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services

    Helsinn Establishes New R&D Hub in the U.S.

    CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Vector Partners Limited

    Biosynth Carbosynth

    IDT Biologika

    Quotient Sciences
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Vector Partners Limited

    Biosynth Carbosynth

    IDT Biologika

    Quotient Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CEO Spotlight: Darren Head

    Bionova Scientific’s chief executive talks about the company’s beginnings and its fast growth, having recently been acquired by Asahi Kasei Medical.

    CEO Spotlight: Darren Head
    Darren Head, CEO, Bionova Scientific
    Tim Wright, Editor, Contract Pharma05.02.22
    Bionova Scientific is a full-service biologics contract development and manufacturing organization (CDMO) with a staff of more than 100 employees in the heart of the San Francisco Bay biotech cluster. It operates a state-of-the-art 11,000 square foot commercial-ready GMP biologics manufacturing facility located within its 57,000 square foot headquarters, which also houses process development and analytical laboratories. Bionova facilities also include a second 22,000 square foot building with GMP warehouse space.

    A portfolio company of Great Point Partners (GPP), a Greenwich-based private investment firm focused exclusively on the health care industry, Bionova announced as this story went to press an agreement to be acquired by Asahi Kasei Medical (see side bar below).

    Contract Pharma recently talked with Bionova’s chief executive officer, Darren Head, about the company’s beginnings and its rapid growth led by a driven team of scientists dedicated to improving patients’ lives.

    Contract Pharma: What led you to your role as chief executive at Bionova Scientific?

    Darren Head:
    I’ve had the privilege of working at some great CDMOs before Bionova, most recently leading Cytovance and MaSTherCell. Through those two companies, I developed a relationship with Great Point Partners (GPP), a private equity firm that specializes in life sciences services companies, such as CDMOs. When GPP was looking at an investment in Bionova, they asked me to participate in the due diligence process. I was deeply impressed with the scientific talent at the company and saw great promise for its future if they could secure greater access to capital. In this business, anyone with money can buy the latest technology and build a shiny facility, but the most critical and hardest-to-find building block is talented people with scientific know-how and discipline. Bionova had a stronger scientific core than any CDMO I had seen.

    I also saw that clients loved Bionova. In many cases, the only frustration we heard was that clients wanted to stick around with us for manufacturing, but we did not yet offer that capability. We saw a great opportunity to support Bionova so the company could provide a full range of CDMO services for its clients.

    So, GPP made the investment in Bionova and then I was named chairman, where I got to work closely with the founders, Amy Kong and Chung Chun. As the company continued its rapid growth and we moved closer to Amy and Chung’s vision of adding GMP manufacturing for recombinant protein biologics, the founders were itching to get back to their scientific roots and asked me to move into the CEO role.

    CP: Can you share a bit of background and history on the company?

    Head:
    The company’s history is really Amy and Chung’s story. They were colleagues and friends at prior biotech companies, including Amgen, Abgenix and Boehringer Ingelheim. Amy and Chung had established very strong scientific reputations and decided they wanted to build their own company. As the story goes, they wanted to build a science-based business where clients came first and mutual trust was a cornerstone.

    Amy and Chung set out to find like-minded, highly talented people and bring them together in an environment that allowed for entrepreneurial spirit and agility and personal touch. In retrospect, it is amazing the level of scientific talent they were able to attract to this little start-up company. They also invested heavily in technology, so their team would have the best tools with which to do their work.

    But their real focus was to build a workplace where people were empowered and energized to do great work together for clients—where they would not let big company meetings and bureaucracy slow them down. They were committed to a responsive, caring culture that gave all clients confidence that their critical projects would be handled well. That was Amy and Chung’s vision then and it very much lives on in Bionova today.

    That early vision worked and Bionova was able to build up a portfolio of clients, small and large, including many in the Bay Area. Those early clients proved to be very loyal, and many still work with the company today. In fact, we recently completed our first clinical GMP run for one of our early clients. Through word of mouth, those loyal clients also sent many others our way, so the company was able to sustain a rapid growth trajectory. In 2019, GPP got involved and made an investment which enabled us to construct a new GMP manufacturing facility, setting us up for the next phase of growth.

    CP: It sounds like science and culture are equally important parts of the company’s success. How do you sustain the culture as the company grows?

    Head:
    The nice thing about leading a company in this industry is that the inspiration is served to us on a silver platter. Every day, we get to work with clients who have developed an innovation that could save the lives of thousands of patients, or improve the quality of life for millions of people. The fact that we get to contribute to making that happen for patients with cancer, autoimmune disease and many other disease areas makes it much easier to be motivated to come to work every day, stay late or work on a weekend. In a world that can seem pretty cynical, it’s refreshing to know that our work really does make a difference for people.

    Our founders and our current leadership team do not take this for granted. We remind our team every day that their work matters, that their extra effort could lead to a life-saving drug getting to market sooner and therefore saving a life that might not otherwise have a chance. As CEO, one of my main jobs is to remove obstacles that get in the way of our team. Sometimes that means making an investment in technology, but more often than not, it means helping our various groups continue to communicate and to focus on what’s important.

    CP: What are some of the exciting areas you’re seeing in biologics these days?

    Head:
    Well like I said, Bionova was built around a deep core of science and our focus was recombinant protein therapeutics. As we attracted such a strong team, this naturally led to us helping clients with their most difficult programs or difficult-to-manufacture biologics. There are lots of small “virtual” biotechs that are focused on discovery and are working on some exciting concepts such as bispecific, trispecific, antibody fragments, enzymes, ADCs and non-traditional protein molecules. These companies do not want to invest in headcount and facilities to handle the development work and even more for manufacturing, so they are more likely to rely on companies like Bionova to act as their outsourced development and manufacturing partner. As we helped one client after another with this kind of work, we became the experts in that space, so we tend to see a lot of really exciting concepts coming through the building. We’re finding that even large companies are calling on us to leverage our special expertise in this area. I wish I could share specifics of some of the programs in the works, but client confidentiality is non-negotiable!

    CP: You built a new GMP manufacturing facility during the Covid pandemic. What were some of the challenges you faced?

    Head:
    Our board approved the investment in the GMP facility just a few months before the rest of the world came to a standstill due to COVID. So, we were deep into our planning in Q1 2020 when we suddenly had to deal with the disruptions the pandemic would present.

    Thankfully, our team was excited to push forward, and they did a remarkable job rallying to sustain the project’s momentum. A complex project like this requires an extraordinary level of collaboration and coordination, across our own internal teams, with architects, engineers, contractors, equipment and technology providers, government officials, and so on. It wasn’t easy, but I am so grateful to everyone involved for the way they came together and stayed focused on getting the job done.

    We broke ground in July 2020 while the rest of the world was getting used to “work from home.” A little over a year later we had a state-of-the-art, commercial-ready biologics manufacturing facility that had been completed on-time and on-budget. It is really a tribute to the entire team and something we are immensely proud of.

    As an aside, what sometimes gets lost in this conversation is that we also had a rapidly growing CDMO business with critical cell line development, process development and other projects that had to keep moving. The pandemic also triggered a new wave of projects for COVID-related treatments, so our development teams were operating at full capacity. Our teams demonstrated great commitment and perseverance to keep our client programs moving forward while also supporting the facility design work. It was a very difficult period for everyone to go through, but the end-result is really awe-inspiring.

    CP: You’ve mentioned the new GMP facility a few times. What more can you tell us about it?

    Head:
    In designing the GMP facility, we were fortunate to have several team members who had operated GMP facilities for other companies, so we had a very good idea of what we did and did not want. We also knew that we could not accurately predict where our clients or the industry would take us, so we focused on versatility and future-proofing as much as possible.

    This led us to an all single-use, open ballroom design. This design would give us maximum flexibility to handle different scales of process, to handle complex molecules that might require four or five purification steps (as opposed to the usual three), perfusion processes, or different hold times/temperatures. We designed that flexibility into the facility so we could bring nearly any piece of advanced equipment in while supporting it from a robust quality systems standpoint.

    One of the nice things about building a brand-new facility with no legacy issues is we are able to benefit from all the latest and greatest technologies and can bring in new equipment and technology faster than any CDMO I know of. While we are doing early-stage clinical manufacture today, we have the systems and infrastructure to handle commercial manufacture when the time comes, so we can support clients all the way through the product life cycle.

    We also designed the facility to address current and future regulatory requirements. The biggest change we face from a regulatory standpoint is the globalization of requirements. If we want to support clients in front of the FDA, EMA and other jurisdictions, our facility must accommodate ALL requirements from ALL jurisdictions. We must also address future proposed requirements. This flexibility is built into our design.

    Another dimension of the facility that was very important to us was visibility. As a company, open, collaborative relationships with clients are a fundamental part of our mindset. We know that clients are hungry to know what is happening with their products and projects, so we sought to design visibility into the facility. The production suites and labs have large viewing windows and we have a large, bright viewing area from which clients can view their product being manufactured. We also have secure cameras throughout the facility, so we can allow clients to look in on their processes when they can’t get into the suite physically.

    I’d be remiss if I didn’t also mention how our team plays into the success of the new GMP manufacturing operation. We now have the same scientists who develop a client’s process participate in the transfer of the process to manufacturing and are available for on-the-floor support and troubleshooting. This allows us to ensure that processes are scaled-up seamlessly.

    CP: Now that your GMP manufacturing facility is operational, what’s next for Bionova?

    Head:
    We are very focused on operating the new facility and are very pleased so far with the results of our first few months’ worth of manufacturing activities. We are also in the early stages of planning our next expansion, which will focus on GMP plasmid DNA manufacturing. There is an enormous amount of activity in advanced cell and gene therapies and mRNA vaccine technology, and that brings with it an urgent need for new sources of high-quality plasmid DNA. We are applying our scientific expertise in process development, QC, analytical and GMP manufacturing and our facility design experience to respond to this demand with a new production facility to be launched in 2023. We’re looking to offer small-scale process development and bench material generation later in 2022, with pre-GMP and GMP production rolling out in 2023.

    CP: You mentioned cell and gene therapies. You’re also involved with a cell therapy CDMO, correct?

    Head:
    Yes, Cellipont Bioservices is another GPP portfolio company where I serve as chairman of the board. It’s interesting, because apart from the scientific focus (cell therapy vs. recombinant protein biologics), Cellipont is in many ways a carbon copy of a younger Bionova. Their core strength is their scientific talent and experience, which they combine with a great commitment to client service. Cellipont has assembled a great team and has some exciting expansion plans in the works. I expect them to become an important player in the cell therapy space over the next few years. 

    Bionova to Become Part of the Asahi Kasei Group
    Will complement Asahi Kasei’s bioprocess consumables & equipment and biosafety testing services business.

    As this issue of Contract Pharma went to press, Bionova Scientific announced an agreement to be acquired by the U.S. arm of Asahi Kasei Medical, a core operating company of the Asahi Kasei Group (led by Asahi Kasei Corp. of Tokyo). The acquisition represents a strategic complementary addition to Asahi Kasei Medical’s bioprocess business, which is known for Planova virus removal filters, MOTIV inline buffer formulation systems, ViruSure viral safety testing services and Bionique mycoplasma safety testing services. With the acquisition of Bionova, Asahi Kasei adds a full-service biologics CDMO in the heart of the San Francisco Bay biotech cluster. Closing of the acquisition is subject to receipt of necessary regulatory clearances.
    Related Searches
    • Biologics, Proteins, Vaccines

    Related Content

      Trending
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Hanmi Fine Chemical Launches CDMO Business | Contract Pharma
      • CureVac, MyNEO Partner On Antigen Targets For MRNA-Cancer Vax Development | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • Insmed Appoints Drayton Wise As Chief Commercial Officer | Contract Pharma
      Breaking News
      • iECURE Enters Agreement with Center for Breakthrough Medicines
      • CPDC Enters Clinical Manufacturing Deal with CellBion
      • Olon to Build New R&D Center in Italy
      • Hanmi Fine Chemical Launches CDMO Business
      • DFE Pharma Opens India CoE for Fast-Track Formulation Services
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      Nippon Paint Automotive Americas Appoints Robert Angart CEO and President
      Sustainability, Economy are Focus of BCF’s Annual Conference
      Demand for Rhino Shield Increases
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 28
      New Breast Implant Surgery Guidelines to Enhance Patient Safety
      Rhythm Management Group Debuts RhythmSynergy Tech Platform
      Contract Pharma

      Latest Breaking News From Contract Pharma

      iECURE Enters Agreement with Center for Breakthrough Medicines
      CPDC Enters Clinical Manufacturing Deal with CellBion
      Olon to Build New R&D Center in Italy
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      K-Beauty Brand Siita Shares Plastic Decomposition Technology with the Beauty Industry
      Shellworks Raises $6.2 Million in Seed Funding
      Ulta Beauty Reports Record First Quarter 2022 Results
      Happi

      Latest Breaking News From Happi

      Global Skincare Treatment Devices Market Expected to Grow at Over 11.5% CAGR Rate Through 2028
      Honeywell Addresses Critical Issues Such as Sustainability, Workforce Training and Digitalization
      Monat Global Wins Four Stevie Awards in the 20th Annual American Business Awards
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Flint Group, New Inks from Siegwerk and Zeller+Gmelin Lead This Week’s News
      Orion to Finish Gas Black Expansion in Germany by Early 2023
      Richard Childress Racing Shows Off New Wraps for 2022 NASCAR Season
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      UPM Raflatac accelerates label growth with acquisition
      Labelexpo Asia 2022 postponed
      Teklynx software helps Top Clean Injection validate labels
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most-Read Stories This Week—May 28
      Toetal Solutions Raises $1.02 Million in New Financing
      ManaMed's ManaSport Wearable Ultrasound Earns FDA Nod
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: OPV’s Future, Graphene Flagship and Japan Display Top This Week’s Stories
      SEMI Foundation Receives $1.5 Million Grant to Bolster Michigan’s Semiconductor Talent Pipeline
      onsemi Recognized by Fortune 500 for Its Transformation Journey

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login